Rempex
CompanyUnited States
Rempex develops 2 assets, the furthest approved (minocycline in acne vulgaris). Mostly small molecule acting on inflammation; based in the United States.
- 2
- Assets
- Furthest
- Approved
- 5
- Trials
- 0
- Signals
Pipeline
2Tetracycline antibiotic inhibiting bacterial protein synthesis with anti-inflammatory and neuroprotective properties
Approved, Small molecule, Inflammation, acne vulgaris, Adult Periodontitis
Tetracycline-class broad-spectrum antibiotic that inhibits bacterial protein synthesis.
Phase 1, Small molecule, acute renal insufficiency, chronic renal insufficiency
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials5
- Similar companies6
Updated 8 Oct 2026 · 35 sources